Few studies are available that compare PBSC and BM from unrelated donors, especially in adult high-risk ALL. To determine which graft source is superior in adult high-risk ALL, we analyzed the long-term outcomes of 106 consecutive transplants from 8/8-matched or 7/8-matched unrelated donors (38 PBSC vs 68 BM). All patients received a uniform strategy of pre-transplant therapy, myeloablative conditioning and GVHD prophylaxis. At 5 years, PBSC transplants showed higher incidence of chronic GVHD than did BM transplants (74.3% vs 46.7%, P = 0.001). PBSC transplants showed outcomes comparable to those of BM transplants for relapse (23.7% vs 28.1%), non-relapse mortality (18.4% vs 25.0%), disease-free survival (57.9% vs 46.9%) and OS (57.9% vs 50.0%). In a separate comparison of outcomes between the two graft sources according to the presence of a Ph chromosome, no significant advantage of PBSC over BM was found in both subgroups of patients. Our data suggest that the outcomes of unrelated donor transplantation are similar between PBSC and BM in adult high-risk ALL. Whether PBSC should be the preferred graft source for a specific subgroup of adult ALL needs to be further investigated.
INTRODUCTION
Allo-SCT is a widely accepted post-remission treatment for adults with ALL. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In the setting of HLA-matched sibling donor (MSD) transplantation, several randomized trials showed that PBSC resulted in faster engraftment, but increased the risk of chronic GVHD compared with BM. [11] [12] [13] [14] [15] [16] [17] [18] [19] In addition, some studies showed a decreased rate of relapse and better survival with PBSC, especially in patients with more advanced hematologic malignancies. 15, 17, 18 However, these results may not be applicable to unrelated donor (URD) transplants, given the greater risk of GVHD owing to their greater genetic diversity.
During the last decade, PBSC has become the most common graft source in URD-SCT. However, few studies are available that compare the outcomes of PBSC vs BM transplants in the setting of URD-SCT. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Furthermore, an analysis of the long-term outcomes of URD-SCT according to the graft source has not yet been reported in adults with ALL. In order to determine which graft source is superior in adults with high-risk ALL, we compared the long-term outcomes of URD-SCT between PBSC and BM. The strengths of this study include sufficient follow-up duration and restriction to a single disease with a uniform pre-and posttransplantation treatment strategy.
PATIENTS AND METHODS

Patients and treatment policy
Our center offers allo-SCT as a treatment policy according to donor availability and the presence of high-risk features. [30] [31] [32] [33] [34] Donor-recipient pairs were considered matched when the pair was identical at HLA-A, -B, -C and -DRB1 loci with high-resolution HLA genotyping. If a MSD was available, MSD-SCT was offered to any patient after the completion of the first consolidation course. If a suitably HLA-matched (8/8-matched or 7/8-matched) URD was available, URD-SCT was offered to high-risk patients as early as possible.
Between March 2000 and December 2009, 140 consecutive patients with high-risk ALL underwent URD-SCT. To maximize the homogeneity of the patient population, 106 myeloablative conditioning transplants from URD who underwent a uniform strategy of pre-transplant chemotherapy and GVHD prophylaxis were included in this analysis. Patients who received reduced-intensity conditioning transplantation and transplantation from ⩾ 2 allele-mismatched URD were excluded. Donors were from the domestic registries Korean Marrow Donor Program and Catholic Hematopoietic Stem Cell Bank; n = 87 (28 PBSC and 59 BM), JMDP; n = 2 (0 PBSC and 2 BM), Tzu Chi Marrow Donor Registry of Taiwan; n = 10 (4 PBSC and 6 BM), National Marrow Donor Program of United States; n = 4 (3 PBSC and 1 BM) and Zentrales Knochenmarkspender-Register Deutschland; n = 3 (3 PBSC and 0 BM). Graft source for myeloablative conditioning transplants from URD was purely selected according to each donor's preference. This study was approved by the institutional review board at the Catholic University of Korea. This study was conducted in accordance with the Declaration of Helsinki. Data were analyzed as of June 2013.
Pre-transplantation treatment
Induction therapy was initiated with hyper-fractionated CY (300 mg/m 2 , every 12 h, days 1-3), VCR (1.4 mg/m 2 , maximum dose 2 mg, days 4 and 11), idarubicin (12 mg/m 2 , days 4 and 11) and dexamethasone (40 mg, days 1-4 and days [11] [12] [13] [14] . [30] [31] [32] [33] [34] [35] [36] Subsequently, patients in CR received consolidation courses that consisted of high-dose cytarabine (2 g/m 2 , every 12 h, days 1-5) and mitoxantrone (12 mg/m 2 , days 1-2) therapy (at each odd cycle) alternating with the above induction regimens (at each even cycle), depending on donor availability and the time of transplantation. Central nervous system prophylaxis was performed by intrathecal administration of triple agents (MTX 12 mg, cytarabine 40 mg and methylprednisolone 50 mg; 6 times in total). In addition, patients with Ph-positive ALL received imatinib-based chemotherapy before transplantation.
Transplantation procedures
The preparative regimen consisted of TBI (13.2 Gy) and CY (120 mg/kg).
30
-34 PBSC donors were prescribed lenograstim (10 μg/kg/day for 5 days) and underwent apheresis for 1-2 days with target CD34+ cells ⩾ 3 × 10 6 /kg of recipient's body weight. BM cells were collected from the donors via standard procedures. GVHD prophylaxis was performed by administering tacrolimus plus MTX. [30] [31] [32] [33] [34] [35] [36] If residual leukemia was detected in the absence of GVHD at 3 months after transplantation, tacrolimus was rapidly discontinued.
Definitions
Patients were defined as high-risk ALL if they met at least one of the following criteria at diagnosis: (1) advanced age (⩾35 years); (2) high leukocyte count (⩾30 × 10 9 /L for B-lineage ALL, ⩾ 100 × 10 9 /L for T-lineage ALL); (3) adverse cytogenetics (Ph, t(4;11), t(8;14), complex karyotype or low hypodiploidy-near triploidy); (4) delayed CR1 (>28 days of induction therapy). Neutrophil and platelet engraftment were defined as a neutrophil count of >0.5 × 10 9 /L during the first 3 consecutive days and a platelet count of >20 × 10 9 /L during the first 7 consecutive days, respectively. GVHD was diagnosed and graded using the previously published criteria. 37, 38 Statistical analysis
The main end points of this study included relapse, non-relapse mortality (NRM), disease-free survival (DFS) and OS. Curves for DFS and OS were plotted using the Kaplan-Meier method and compared using the log-rank test. Relapse and NRM were calculated using cumulative incidence estimates and compared using the Gray test. The prognostic significances of covariates affecting DFS and OS were determined using the Cox proportional hazards model. Factors were considered significant if they had an associated P-value of o 0.05, using two-tailed significance testing. The prognostic significances of covariates affecting relapse and NRM were determined using the proportional hazards model for sub-distribution of a competing risk.
RESULTS
Patient characteristics
The main clinical and biological features for all patients are summarized in Table 1 . The median patient age was 23 years (range, 15-48 years). All patients had at least one high-risk factor. Graft sources were PBSC (n = 38; 22 8/8-matched, 16 7/8-matched) and BM (n = 68; 30 8/8-matched, 38 7/8-matched). Eighty-three patients (78.3%) underwent transplantation in CR1 (34 PBSC and 49 BM). PBSC grafts contained higher numbers of CD34+ cells (P = 0.011) and CD3+ cells (Po0.001) than BM grafts. The median follow-up duration of survivors was shorter in the PBSC transplants than in the BM transplants (61 months vs 104 months; Po0.001), because the PBSC transplants were carried out more recently. Other characteristics were comparable between the two graft sources.
Hematopoietic recovery and GVHD PBSC transplants showed faster recovery of neutrophils (12 days vs 14 days; P o 0.001) and platelets (12 days vs 21 days; P o 0.001) than BM transplants ( Table 2 ). The cumulative incidence of acute GVHD at 100 days was 68.4% (95% confidence interval (CI), 50.6-81.0%) in PBSC transplants and 58.8% (95% CI, 46.0-69.6%) in BM transplants (P = 0.182) (Figure 1a ). The cumulative incidence of chronic GVHD at 5 years was higher in PBSC transplants than in BM transplants (74.3% (95% CI, 55.7-86.0%) vs 46.7% (95% CI, 33.6-58.7%); P = 0.001) (Figure 1b ).
Relapse Twenty-eight patients (9 PBSC and 19 BM) experienced relapse at a median of 8 months after transplantation (7 months (range, 3-24 months) for PBSC, 9 months (range, 3-60 months) for BM). The cumulative incidence of relapse at 5 years was 23.7% (95% CI, 11.6-38.2%) for PBSC and 28.1% (95% CI, 17.9-39.2%) for BM (P = 0.675) (Table 2; Figure 2a ). In univariate analysis, the potential factors predicting relapse were adverse cytogenetics (positive vs negative; P = 0.068), disease status at transplantation (>CR1 vs CR1; P = 0.001) and chronic GVHD (negative vs positive; P o 0.001). In multivariate analysis, factors independently associated with higher risk of relapse were transplantation in >CR1 (hazard ratio (HR), 3.02; 95% CI, 1.43-6.38; P = 0.004) and the absence of chronic GVHD (HR, 4.57; 95% CI, 2.03-10.28; P o 0.001) ( Table 3) . NRM Twenty-four patients (7 PBSC and 17 BM) died of causes other than relapse at a median of 4 months after transplantation (6 months (range, 1-24 months) for PBSC, 4 months (range, 1-27 months) for BM). The primary causes of NRM were as follows: chronic GVHD (n = 9; 4 PBSC and 5 BM), acute GVHD (n = 6; 2 PBSC and 4 BM), infection (n = 4; 0 PBSC and 4 BM), organ failure (n = 3; 1 PBSC and 2 BM) and hemorrhage (n = 2; 0 PBSC and 2 BM). The cumulative incidence of NRM at 5 years was 18.4% (95% CI, 8.0-32.2%) for PBSC and 25.0% (95% CI, 15.4-35.8%) for BM (P = 0.430) ( Table 2 ; Figure 2b ). The potential factors predicting higher NRM were advanced age (P = 0.050), delayed CR1 (P = 0.070) and transplantation from 7/8-matched donor (P = 0.066). In multivariate analysis (Table 3) , there were no significant factors affecting NRM. Patients aged ⩾ 35 years showed a tendency toward higher NRM (HR, 2.25; 95% CI, 0.98-5.17; P = 0.057).
Survival
At the time of the analysis, 56 patients (22 PBSC and 34 BM) remained alive and 54 of them (22 PBSC and 32 BM) remained in Figure 2c ). The potential factors predicting poorer DFS were delayed CR1 (P = 0.012), transplantation in >CR1 (P o 0.001), transplantation from 7/8-matched donor (P = 0.007) and the absence of chronic GVHD (P o 0.001). In multivariate analysis ( Figure 2d ). Abbreviations: CI = confidence interval; DFS = disease-free survival; NRM = non-relapse mortality. 
Subgroup analyses
Among the 83 transplants in CR1 (34 PBSC and 49 BM), there was no difference in the incidence of acute GVHD (67.6% vs 61.2%; P = 0.217), relapse (17.6% vs 20.4%; P = 0.780), NRM (20.6% vs 20.4%; P = 0.985), DFS (61.8% vs 59.2%; P = 0.840) and OS (61.8% vs 61.2%; P = 0.979) between the two graft sources. However, PBSC transplants showed a higher incidence of chronic GVHD than BM transplants (77.4% vs 53.3%; P = 0.005) ( Table 2 ). In addition, we analyzed the impact of the graft source on transplantation outcomes according to the presence of a Ph chromosome, separately (Table 2 ; Figure 3 ). In a subgroup of patients with Phnegative ALL (n = 68; 23 PBSC and 45 BM), there was no advantage of PBSC over BM in terms of relapse, NRM, DFS and OS. Similarly, patients with Ph-positive ALL (n = 38; 15 PBSC and 23 BM) showed no significant difference in the rates of acute GVHD, chronic GVHD, relapse, NRM and survival between the two graft sources.
DISCUSSION
Our study is the first to compare the long-term outcomes of URD-SCT using PBSC vs BM in an adult high-risk ALL population who received a uniform treatment strategy. The main finding of this study was that PBSC transplants showed long-term outcomes comparable to those of BM transplants, except that PBSC transplants were associated with a higher incidence of chronic GVHD. However, there was no significant relationship between higher incidence of chronic GVHD with PBSC and subsequent lower risk of relapse compared with BM. We hypothesized that there is no additional benefit from an antileukemic effect of chronic GVHD in the use of PBSC compared with BM in the setting of URD-SCT. Our study was not powered to detect potential differences in survival between the two graft sources, because interpretation of the data was mainly limited by the retrospective analysis with the small number of patients. Therefore, our results should be interpreted with caution. Nevertheless, our findings, indicating higher incidence of chronic GVHD without a survival advantage in the use of PBSC compared with BM, are supported by other URD-SCT studies with sizable populations for various hematologic malignancies. According to data from the Center for International Blood and Marrow Transplantation Research registry, 25 the authors retrospectively compared the outcomes of 331 PBSC transplants and 586 BM transplants from URD. They showed higher rates of acute GVHD (58% vs 45%, P o0.001) and chronic GVHD (56% vs 42%, P o 0.001) in PBSC transplants than in BM transplants, whereas the 3-year probabilities of relapse, NRM, DFS and OS were not different between the two graft sources. Recently, the Blood and Marrow Transplant Clinical Trials Network conducted the first randomized trial of URD-SCT using PBSC (n = 273) vs BM (n = 278) to compare their 2-year survival probability. 29 In the intention-to-treat analysis, there was no difference in 2-year OS (51% vs 46%, P = 0.29). The rates of acute GVHD, relapse, NRM and DFS were similar between PBSC and BM, but the incidence of chronic GVHD was higher in the PBSC group (53% vs 41%, P = 0.01). On the basis of these results, the use of PBSC does not appear to be more beneficial than BM in the setting of URD-SCT. Factors to consider in these studies are the inclusion of various underlying diseases, the heterogeneity of the regimen for conditioning and GVHD prophylaxis and the relatively early outcomes.
It is also possible that the protective effect of chronic GVHD with PBSC vs BM may be prominent in a subgroup of ALL patients; for example, patients with more advanced disease or those with specific chimeric proteins. Several previous data obtained from MSD transplants showed that the use of PBSC increased the incidence of chronic GVHD, but conferred a survival benefit to patients with more advanced hematologic malignancies, mainly by decreasing the risk of relapse. 15, 17, 18 Using individual patient data from randomized trials in the setting of MSD-SCT, Pidala et al. 39 constructed a decision analysis model to determine the best graft source. They demonstrated the superiority of PBSC over BM in both overall and quality-adjusted life expectancy; the only situation in which BM may be preferred is when the 1-year relapse risk is less than 5%. Conversely, except for two studies, 26, 28 there was no survival advantage for one graft type over another in the setting of URD-SCT for various hematologic malignancies. [20] [21] [22] [23] [24] [25] 27, 29, 40 This discrepancy may be attributable to the differences in the sensitivity of underlying disease to graftversus-leukemia effect. According to data from the European Group for Blood and Marrow Transplantation registry, 28 the authors retrospectively compared the use of PBSC (n = 1502) and BM (n = 760) only for AML transplants after myeloablative conditioning transplants URD-SCT. They showed a positive effect of PBSC on NRM and DFS for patients with advanced AML, whereas no significant difference was found between the two graft sources for patients in CR. Bertz et al. 26 also recently reported a survival benefit in the use of PBSC compared with BM in Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; NRM = non-relapse mortality.
85 patients with AML and myelodysplastic syndrome after myeloablative conditioning transplants URD-SCT. Unfortunately, our study was not able to assess the impact of the graft source on transplantation outcomes according to disease status at transplantation, because only a few patients received transplantation beyond CR1. However, in line with other studies, [20] [21] [22] [23] [24] [25] [27] [28] [29] our data showed nearly identical outcomes in terms of relapse, NRM, DFS and OS between the two graft sources among transplants in CR1. Therefore, further follow-up with a sizable population is required to define the advantages of URD-SCT using PBSC compared with BM in advanced ALL.
The question of which subgroups of ALL with specific chimeric proteins can benefit from URD-SCT using PBSC compared with BM remains to be answered. When we analyzed the impact of the graft source on transplantation outcomes in patients with Phpositive and Ph-negative ALL, separately, no significant advantage of PBSC over BM was found in both subgroups of patients. However, the small number of each subgroup of patients in the analysis limits the validity of our study. Previously, Elmaagacli et al. 41 reported that PBSC was associated with more rapid engraftment, improved immune reconstitution, lower molecular and cytogenetic relapse rates, and improved survival in patients with chronic-phase CML undergoing URD-SCT when compared with BM. Further studies of adult ALL on a larger scale are warranted to determine whether subgroups of ALL with specific chimeric proteins can benefit from URD-SCT using PBSC.
Despite the need for prospective randomized studies comparing PBSC vs BM using a large and homogenous series of patients with adult ALL, we did not detect a significant advantage of PBSC over BM in patients receiving URD-SCT for adult high-risk ALL. In the future, assessment of the overall benefits of PBSC compared with BM will require continued long-term evaluation of quality of life and follow-up of morbidity and mortality associated with chronic GVHD in long-term survivors. Furthermore, whether PBSC should be the preferred graft source for adult high-risk ALL, according to disease status at transplantation as well as the presence of targeted fusion proteins for donor immune cells, needs to be further investigated. 
